Affimed N.V. (AFMD)
NASDAQ: AFMD
· Real-Time Price · USD
0.18
-0.00 (-0.83%)
At close: May 19, 2025, 3:59 PM
-0.83% (1D)
| Bid | 0.18 |
| Market Cap | 2.98M |
| Revenue (ttm) | 877K |
| Net Income (ttm) | -69.97M |
| EPS (ttm) | -5.09 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.12 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 0.2 |
| Volume | 22,062,730 |
| Avg. Volume (20D) | 15,647,530 |
| Open | 0.22 |
| Previous Close | 0.18 |
| Day's Range | 0.18 - 0.22 |
| 52-Week Range | 0.02 - 8.95 |
| Beta | 2.07 |
| Ex-Dividend Date | n/a |
About AFMD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AFMD
Website n/a
Affimed N.V. is scheduled to release its earnings on
Jun 20, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-2.99%
AFMD stock has given up its prior loss. Affimed sh...
Unlock content with
Pro Subscription
4 months ago
-2.99%
Affimed shares are trading lower after the company announced it received a Nasdaq delisting notice. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight and cut its price target from $11 to $0.1.
5 months ago · https://www.marketscreener.com
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual MeetingAn exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improv...